Live Breaking News & Updates on மேரி குஷ்மேன்|Page 3
Stay updated with breaking news from மேரி குஷ்மேன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
لماذا النساء الأصغر سنا أكثر عرضة للإصابة بجلطات الدم رغم تطعيمهن؟ greenarea.me - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from greenarea.me Daily Mail and Mail on Sunday newspapers.
tayyar.org - لماذا النساء الأصغر سنا أكثر عرضة للإصابة بجلطات الدم رغم تطعيمهن؟ tayyar.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tayyar.org Daily Mail and Mail on Sunday newspapers.
email article Thromboembolic and bleeding risk has been cited by a number of countries in halting use of AstraZeneca s COVID-19 vaccine, but the company and health agencies argued against a causal link. Denmark and Norway were first to stop administering AstraZeneca s vaccine last week over isolated cases of bleeding, blood clots, and low platelet count. Others followed. Germany and France on Monday became the latest to announce a pause in administration. Germany cited seven cases of cerebral vein thrombosis among patients getting one of the 1.6 million AstraZeneca shots given there so far. German Health Minister Jens Spahn call this a very low risk but above average if confirmed to be linked to the vaccine. ....
Related Company: Vermont Business Magazine In large clinical trial conducted worldwide, full dose anti-coagulation (blood thinner) treatments given to moderately ill patients hospitalized for COVID-19 reduced the requirement of vital organ support such as the need for ventilation. A trend in possible reduction of mortality was also observed and is being further studied. With large numbers of COVID-19 patients requiring hospitalization, these outcomes could also help reduce the overload on intensive care units around the world. Dr Mary Cushman, at the University of Vermont s Larner College of Medicine, is a lead investigator on one aspect of the trial. The trial does not include any Vermont patients. ....